- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05706116
Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults
A Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Open-label, dose-escalation clinical study in healthy, trichuriasis-naïve adults:
Study sites:
- George Washington University, Washington, DC
- Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
- Number of participants: up to 18 in 3 cohorts of 6 volunteers each
In Cohort 1, six (6) volunteers will receive an inoculum of 150 embryonated Trichuris trichiura eggs. In Cohort 2, six (6) volunteers will receive an inoculum of 300 embryonated Trichuris trichiura eggs. In the optional Cohort 3, six (6) volunteers will receive an inoculum of 450 embryonated Trichuris trichiura eggs.
The cohorts will be enrolled in a staggered fashion with safety data assessed prior to larval dose escalation. Cohort 2 will be inoculated no earlier than 16 weeks after the last volunteer is inoculated in Cohort 1. The optional Cohort 3 will be inoculated no sooner than 16 weeks after the last volunteer is inoculated in Cohort 2. Cohort 3 will be enrolled only if the tolerability of the experimental infection of Cohort 2 is acceptable and does not result in significant adverse events.
- Egg administration schedule: Study Day 0 (single administration)
- Route: oral
- Doses of T. trichiura Egg Inoculum to be tested: 150, 300 and 450 embryonated eggs (high dose optional)
- Study duration: approximately 10 months per study participant
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: David Diemert, MD
- Phone Number: 202-994-2909
- Email: ddiemert@gwu.edu
Study Contact Backup
- Name: Laura Vasquez, MPH
- Phone Number: 202-994-1599
- Email: lvasquez@gwu.edu
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- George Washington University Medical Faculty Associates
-
Contact:
- Caroline Thoreson, PA-C
- Phone Number: 202-741-2443
- Email: cthoreson@mfa.gwu.edu
-
Principal Investigator:
- David J Diemert, MD
-
Sub-Investigator:
- Elissa Malkin, DO
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- NIH Clinical Center
-
Contact:
- Thomas Nutman, MD
- Phone Number: 301-496-5399
- Email: tnutman@niaid.nih.gov
-
Principal Investigator:
- Thomas Nutman, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males or females between 18 and 45 years, inclusive.
- Good general health as determined by means of the screening procedures.
- Available for the duration of the trial (approximately 7.5 months).
- Willingness to participate in the study as evidenced by signing the informed consent document.
Exclusion Criteria:
- Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female).
- Participant unwilling to use reliable contraception methods while participating in the study (if female of reproductive potential who is engaging in sexual activity that could lead to pregnancy); being of reproductive potential is defined as not being surgically sterile, abstinent from intercourse with a male partner, in a monogamous relationship with a vasectomized partner, at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile.
- Currently lactating and breast-feeding (if female).
- Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies.
- Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits/procedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide).
- Known or suspected immunodeficiency or immunosuppression as a result of an underlying illness or treatment.
- Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25-times the upper reference limit).
- Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit).
- Laboratory evidence of hematologic disease (hemoglobin <11.1 g/dl [females] or <12.5 g/dl [males]; absolute leukocyte count <3.4 or >11.0 x 103/mm3; absolute eosinophil count >0.6 x 103/mm3 or platelet count <125 x 103/mm3).
- Positive fecal occult blood test.
- Infection with a pathogenic intestinal helminth as determined by stool examination for ova and parasites.
- History of iron deficiency anemia or laboratory evidence of iron deficiency (serum ferritin concentration below the lower reference limit).
- Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the participant unable to comply with the protocol.
- Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 24 months.
- Positive ELISA for hepatitis B surface antigen (HBsAg).
- Positive confirmatory test for HIV infection.
- Positive confirmatory test for hepatitis C virus (HCV) infection.
- Using or intends to continue using oral or parenteral corticosteroids, high-dose inhaled corticosteroids (>800 μg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days of the volunteer's expected enrollment in this study or planned use during the study.
- Known allergy to albendazole.
- History of previous infection with T. trichiura or continuous residence for more than 6 months in a T. trichiura-endemic area.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trichuris trichiura Egg Inoculum 150 eggs
150 Trichuris trichiura eggs
|
Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV.
Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use.
Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
|
Experimental: Trichuris trichiura Egg Inoculum 300 eggs
300 Trichuris trichiura eggs
|
Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV.
Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use.
Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
|
Experimental: Trichuris trichiura Egg Inoculum 450 eggs
450 Trichuris trichiura eggs
|
Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV.
Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use.
Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Solicited adverse events, graded by severity
Time Frame: Day of CHTI through study Day 182
|
Frequency of solicited adverse events, graded by severity, from the day of CHTI through study Day 182.
|
Day of CHTI through study Day 182
|
Serious Adverse Events
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of CHTI-related Serious Adverse Events from the time of administration of the T. trichiura Egg Inoculum through the final study visit
|
Day of CHTI through final study visit on study Day 203
|
Unsolicited adverse events
Time Frame: Day of CHTI through study Day 182
|
Frequency of unsolicited adverse events, graded by severity, from the time of CHTI through treatment with albendazole (Day 182)
|
Day of CHTI through study Day 182
|
New-onset chronic medical conditions
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of new-onset chronic medical conditions through the final study visit
|
Day of CHTI through final study visit on study Day 203
|
Adverse Events of Special Interest
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of Adverse Events of Special Interest through the final study visit
|
Day of CHTI through final study visit on study Day 203
|
Adverse events related to abnormal clinical safety laboratory parameter (white blood cell count) values
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of clinical safety laboratory adverse events related to abnormal white blood cell count (unit of measure = cells/mm^3)
|
Day of CHTI through final study visit on study Day 203
|
Adverse events related to abnormal clinical safety laboratory parameter (absolute eosinophil count) values
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of clinical safety laboratory adverse events related to abnormal eosinophil count (unit of measure = cells/mm^3)
|
Day of CHTI through final study visit on study Day 203
|
Adverse events related to abnormal clinical safety laboratory parameter (platelet count) values
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of clinical safety laboratory adverse events related to abnormal platelet count (unit of measure = cells/mm^3)
|
Day of CHTI through final study visit on study Day 203
|
Adverse events related to abnormal clinical safety laboratory parameter (hemoglobin concentration) values
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of clinical safety laboratory adverse events related to abnormal hemoglobin concentration (unit of measure = g/dL)
|
Day of CHTI through final study visit on study Day 203
|
Adverse events related to abnormal clinical safety laboratory parameter (serum creatinine concentration) values
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of clinical safety laboratory adverse events related to abnormal serum creatinine concentration (unit of measure = mg/dL)
|
Day of CHTI through final study visit on study Day 203
|
Adverse events related to abnormal clinical safety laboratory parameter (serum alanine aminotransferase concentration) values
Time Frame: Day of CHTI through final study visit on study Day 203
|
Frequency of clinical safety laboratory adverse events related to abnormal serum alanine aminotransferase (ALT) concentration (unit of measure = U/L)
|
Day of CHTI through final study visit on study Day 203
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fecal egg detection
Time Frame: Day of CHTI through study Day 182
|
Proportion of participants with detectable T. trichiura eggs, at any time point, in fecal samples, as determined by microscopy using the qualified saline flotation technique
|
Day of CHTI through study Day 182
|
Fecal egg counts
Time Frame: Weeks 12 through 26 post-CHTI
|
Fecal egg counts as determined by microscopy using the qualified McMaster method, during Weeks 12 through 26 post-CHTI
|
Weeks 12 through 26 post-CHTI
|
T. trichiura DNA in fecal samples
Time Frame: Weeks 12 through 26 post-CHTI
|
Levels of T. trichiura DNA in fecal samples, as measured by qPCR, during Weeks 12 through 26 post-CHTI
|
Weeks 12 through 26 post-CHTI
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum cytokine concentrations
Time Frame: Weeks 12 through 26 post-CHTI
|
Serum cytokine concentrations during Weeks 12 through 26 post-CHTI
|
Weeks 12 through 26 post-CHTI
|
Cytokine concentrations of supernatants after stimulation of peripheral blood mononuclear cells (PBMCs) with T. trichiura antigen
Time Frame: Day of CHTI through final study visit on study Day 203
|
Cytokine responses to stimulation with T. trichiura and other microbial antigens for total blood cells and peripheral blood monocytes (PBMCs) from the blood
|
Day of CHTI through final study visit on study Day 203
|
Fecal microbiome
Time Frame: Day of CHTI through final study visit on study Day 203
|
Microbial communities present in the fecal samples by DNA and/or RNA sequencing analyses prior to and after exposure to T. trichiura Egg Inoculum
|
Day of CHTI through final study visit on study Day 203
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHTI-01-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trichuriasis
-
Asociacion Benefica PrismaUniversity of Iowa; National Institutes of Health (NIH); University of Virginia; Policlinico Asociacion Benefica PRISMA-Laboratorio Satelite IQTLABNot yet recruiting
-
Jennifer KeiserVector Borne & Neglected Tropical Disease Control Division, Ministry of Health...Completed
-
Jennifer KeiserLao Tropical and Public Health Institute; Centre Suisse de Recherches Scientifiques... and other collaboratorsCompletedTrichuriasisCôte D'Ivoire, Tanzania, Lao People's Democratic Republic
-
Alejandro KrolewieckiBrock University; Universidad Nacional del Centro de la Provincia de Buenos... and other collaboratorsCompletedHelminthiasis | Trichuris InfectionArgentina, Honduras
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano HerediaWithdrawn
-
Swiss Tropical & Public Health InstitutePublic Health Laboratory Ivo de CarneriCompletedTrichuris Trichiura; InfectionTanzania
-
Natural History Museum, United KingdomUniversity of London; Ministry of Health, TanzaniaCompletedAscariasis | TrichuriasisTanzania
-
Jennifer KeiserCentre Suisse de Recherches Scientifiques en Cote d'IvoireCompletedHookworm Infections | TrichuriasisCôte D'Ivoire
-
University GhentVLIR-UOS Institutional University CooperationCompletedInfection by Trichuris TrichiuraEthiopia
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriNot yet recruitingHookworm Infections | Ascariasis | TrichuriasisTanzania
Clinical Trials on Trichuris trichiura Egg Inoculum
-
University of AarhusCompletedHelminthiasis | Helminth Infection
-
University of AarhusCompletedCrohn Disease | Colitis, Ulcerative | Intestinal Helminthiasis
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Anemia, Aplastic | Pancytopenia | Blood Disease